SII, Bharat Biotech together pledge towards smooth roll out of covid vaccines

at 5:53 pm
vaccine cold chain storage sites

New Delhi (NVI): Serum Institute of India (SII) and Bharat Biotech have issued a statement in which the companies pledged to work jointly on the COVID-19 vaccine rollout project.

“Serum Institute of India and Bharat Biotech Jointly communicate their pledge towards a smooth rollout of Covid-19 vaccines to India and the world,” the statement read.

SII CEO Adar Poonawala and Bharat Biotech chairman Krishna Ella, jointly on behalf of the two companies, today communicated their combined intent to develop, manufacture and suplly the COVID-19 vaccines for India and globally, the statement added.

They said, “The more important task in front of them is saving the lives and livelihoods of populations in India and the world. Vaccines are a global public health good and they have the power to save lives and accelerate the return to economic normalcy at the earliest.”

The joint statement further added, “Now that two COVID vaccines have been issued EUA (emergency use authorization) in India, the focus is on manufacturing, supply and distribution, such that populations that need it the most receive high quality, safe and efficacious vaccines.”

“Both our companies are fully engaged in this activity and consider it our duty to the nation and the world at large to ensure a smooth rollout of vaccines. Each of our companies continue their Cmore important task in front of them is saving the lives and livelihoods-19 vaccines development activities as planned,” it stated.

The firms added, “We are fully aware of the importance of vaccines for people and countries alike, we hereby communicate our joint pledge to provide global access for our Covid-19 vaccines.”

Bharat Biotech’s Covaxin was approved for emergency use by Drug Controller General of India (DCGI) on Sunday along with Oxford Covid-19 vaccine Covishield, manufactured by the Serum Institute of India.

The Drugs Controller General of India (DCGI) granted approval on the basis of recommendations by a COVID-19 Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).